Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Next Previous
Search
Trial Profile

A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 23 Apr 2025 According to a BriaCell Therapeutics Corp Media Release, company will publish a abstract with data from this study in 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30-June 3 at McCormick Place, Chicago, IL.
  • 19 Apr 2023 Results (n=51) assessing the safety and efficacy of SV-BR-1-GM in combination with a PD1 inhibitor and post-hoc exploratory data for patients with advanced metastatic breast cancer treated with SV-BR-1-GM regimens from (NCT03328026; 2018-present) and (NCT03066947; 2013-8) trials, presented at the 114th Annual Meeting of the American Association for Cancer Research.
  • 10 Dec 2022 pooled/post hoc analysis results from NCT03328026 and NCT03066947; analyzing the predictive value of CTCs & CAMLs, CAML PD-L1 expression, isolated from patients peripheral blood pre & post treatment to predict drug response, presented at the 45th Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top